MENU
+Compare
SRDX
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$36.88
Change
+$0.24 (+0.66%)
Capitalization
397.04M

SRDX Surmodics Forecast, Technical & Fundamental Analysis

a provider of surface modification and in vitro diagnostic technologies to the healthcare industry

SRDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for SRDX with price predictions
Jan 08, 2025

SRDX in downward trend: price dove below 50-day moving average on January 07, 2025

SRDX moved below its 50-day moving average on January 07, 2025 date and that indicates a change from an upward trend to a downward trend. In of 42 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

SRDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 174 cases where SRDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SRDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.250) is normal, around the industry mean (23.424). P/E Ratio (71.513) is within average values for comparable stocks, (83.627). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (2.838) is also within normal values, averaging (41.167).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

View a ticker or compare two or three
SRDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

SRDX is expected to report earnings to fall 51.37% to -11 cents per share on January 30

Surmodics SRDX Stock Earnings Reports
Q4'24
Est.
$-0.12
Q3'24
Beat
by $0.07
Q2'24
Beat
by $0.07
Q1'24
Beat
by $0.42
Q4'23
Beat
by $0.27
The last earnings report on November 06 showed earnings per share of -23 cents, beating the estimate of -31 cents. With 410.74K shares outstanding, the current market capitalization sits at 397.04M.
A.I. Advisor
published General Information

General Information

a provider of surface modification and in vitro diagnostic technologies to the healthcare industry

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
9924 West 74th Street
Phone
+1 952 500-7000
Employees
376
Web
https://www.surmodics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TGIHX15.510.15
+0.98%
Nuveen Core Equity I
NSFGX12.000.04
+0.33%
Natixis Target Retirement 2035 N
TPIAX12.930.02
+0.15%
Timothy Plan International A
ARIFX11.02N/A
N/A
Aristotle International Eq I
MCCPX20.87N/A
N/A
BlackRock Sustainable Balanced Inv C

SRDX and Stocks

Correlation & Price change

A.I.dvisor tells us that SRDX and RMD have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SRDX and RMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRDX
1D Price
Change %
SRDX100%
+0.66%
RMD - SRDX
32%
Poorly correlated
+1.12%
LIVN - SRDX
31%
Poorly correlated
+0.67%
TMDX - SRDX
29%
Poorly correlated
-1.41%
MBOT - SRDX
26%
Poorly correlated
-7.87%
VNRX - SRDX
26%
Poorly correlated
-2.17%
More